This is a Phase 3, multi-center, randomized, double-blind study to determine the efficacy and
safety of MLT, a novel antibiotic lock therapy that combines minocycline with edetate
disodium in 25% ethanol solution.
Approximately 700 subjects who have been diagnosed with CRBSI/CLABSI and who meet all
necessary criteria for the study will be randomized in a 1:1 ratio to 1 of 2 treatment arms:
- MLT Arm: MLT + SOC intravenous (IV) antibiotic therapy; or
- Control Arm (subjects randomized to the Control Arm will receive treatment based on the
type and virulence of the infecting organism as documented by the Investigator prior to